Search clinical trials for: 2-deoxy-D-glucose (2DG)

Total 2170 results

Jichi Medical University
Eli Lilly and Company; Boehringer Ingelheim

Completed

SGLT-2i and ARB Combination Therapy in Patients With T2DM and Nocturnal Hypertension (SACRA Study)

T2DM (Type 2 Diabetes Mellitus) | Nocturnal Hypertension

Japan
University Health Network, Toronto
AstraZeneca; University of Toronto; Toronto General Hospital

Completed

Treating to Reduce Albuminuria and Normalize Hemodynamic Function in Focal ScLerosis With dApagliflozin Trial Effects (TRANSLATE)

Focal Segmental Glomerulosclerosis

Canada
AstraZeneca
Monash University

Terminated

forREAL: FORXIGA PRESCRIPTION EVENT MONITORING PROGRAM (PEMP) (forREAL)

Type 2 Diabetes

Australia
Kinderkrankenhaus auf der Bult

Completed

Phase 1 Study to Explore the Safety and Pharmacokinetics of DAPAglifozin in Adolescents and Adults With Type 1 Diabetes (DAPA-IIT1)

Type 1 Diabetes

Germany
Astellas Pharma Inc

Completed

The Survey of Ipragliflozin Treatment in Elderly type2 Diabetes Patients (STELLA-ELDER)

Type 2 Diabetes

Japan
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Pharmacokinetic and Bioavailability Study of 28431754 (Canagliflozin) in Healthy Male Volunteers

Healthy

Belgium
AstraZeneca
Bristol-Myers Squibb

Completed

Study to Assess the Effect of Food on Combination Dapagliflozin/Metformin Tablet in Healthy Volunteers

Healthy

Sweden
Boehringer Ingelheim

Not yet recruiting

A Study to Test Whether BI 690517 in Combination With Empagliflozin Helps People With Heart Failure

Heart Failure
Sichuan Academy of Medical Sciences

Recruiting

Dapagliflozin Delays the Loss of Renal Function in Peritoneal Dialysis Patients

Peritoneal Dialysis Complication | Renal Function Aggravated | Sodium-glucose Co-transporter-2 Inhibitors

China
Handok Inc.

Not yet recruiting

Pharmacokinetics of HD-P023 and Co-administration of Teneligliptin and Empagliflozin High in Healthy Volunteers

Healthy Volunteers
Assiut University

Not yet recruiting

Using of SGLt2 Inhibitors in Patients With Type 2 DM

Type 2 Diabetes
University of Colorado, Denver

Recruiting

Efficacy and Mechanisms of Dapagliflozin in Promoting Kidney Function and Cardiovascular Health in Kidney Transplant Recipients

Vascular Diseases | Diabetes | Kidney Transplant; Complications

United States
Shanghai 10th People's Hospital

Recruiting

SGLT2 Inhibitors in Treating Patients With PCOS

Polycystic Ovary Syndrome

China
The First Affiliated Hospital of Dalian Medical...

Recruiting

Huangqi Guizhi Wuwu Decoction in CKD Stage 2-4 Diabetic Nephropathy

Diabetic Nephropathies

China
Juntendo University
Boehringer Ingelheim

Recruiting

Early Treatment With a Sodium-glucose Co-transporter 2 Inhibitor in High-risk Patients With Acute Heart Failure (EMPA-AHF)

Acute Heart Failure

Japan
Zealand University Hospital

Not yet recruiting

Treatment With SGLT-2 Inhibitor for Postoperative Hyperglycemia in Acute Abdominal Surgery - a Randomized Trial

Stress Hyperglycemia | Postoperative Hyperglycemia
Dong-A University

Recruiting

Short-term Use of Dapagliflozin to Protect Kidney Function in CKD Patients

Renal Insufficiency, Chronic | Percutaneous Coronary Intervention | Cardiac Catheterization

Korea, Republic of
University of Oklahoma

Recruiting

Dapagliflozin in Patients With Atrial Fibrillation (DAPA-AF)

Diabetes Mellitus | Atrial Fibrillation

United States
RenJi Hospital

Recruiting

The Safety of Dapagliflozin in Hemodialysis Patients With Heart Failure (SDHF)

Hemodialysis Complication

China
Jacob Moller
Rigshospitalet, Denmark; University Hospital Bispebjerg and Frederiksberg; Hillerod... and other collaborators

Recruiting

The Cardiac Effects of Empagliflozin in Patients With High Risk of Heart Failure

Heart Failure | Obesity

Denmark
West China Hospital

Not yet recruiting

Ameliorating Metabolic Profiling After Kidney Transplantation (AMPKT)

Kidney Transplantation | Metabolic Disorder | Metformin | Empagliflozin
Xiangtan Central Hospital
ZhuZhou Central Hospital; Second Xiangya Hospital of Central South University

Recruiting

Association Between Dapagliflozin-induced Improvement and Anemia in Heart Failure Patients (ADIDAS) (ADIDAS)

Heart Failure | Anemia

China
Andrea Giaccari

Recruiting

Effects of SGLT2 Inhibition on Myocardial Insulin Sensitivity (DapaHeart)

Type2 Diabetes Mellitus | Stable Coronary Artery Disease

Italy
University of Pennsylvania
Amgen

Completed

Effect of Dapagliflozin on Submaximal Exercise Tolerance in Heart Failure

HFrEF

United States
University of Liverpool
AstraZeneca; Clinical Practice Research Datalink

Active, not recruiting

A Pragmatic Randomized Trial to Evaluate the Comparative Effectiveness Between Dapagliflozin and Standard of Care in Type 2 Diabetes Patients (DECIDE)

Type 2 Diabetes Mellitus

United Kingdom
Mansoura University

Completed

Effect of Dapagliflozin in Patients With Acute Heart Failure (DAPA-RESPONSE-AHF)

Acute Heart Failure

Egypt
University Hospital Inselspital, Berne
Boehringer Ingelheim; University of Bern

Completed

Impact of the SGLT2 Inhibitor Empagliflozin on Urinary Supersaturations in Kidney Stone Formers (SWEETSTONE)

Kidney Stone

Switzerland
Postgraduate Institute of Medical Education and...

Completed

Evaluation of Changes in Pancreatic Fat Content Using Advanced MR Sequences in Diabetics on Dapagliflozin Therapy

Pancreatic Lipomatosis

India
Ain Shams University

Completed

Effect of Glucuronosyltransferase (UGT) Genetic Variation on Pharmacokinetics of Empagliflozin

Pharmacokinetics | Pharmacogenomic

Egypt
CHEOL WHAN LEE, M.D., Ph.D

Terminated

Effects of dapaglifloziN Therapy on Myocardial Perfusion Reserve in Prediabetic Patients With Stable coronarY Artery Disease

Coronary Artery Disease | Prediabetic State

Korea, Republic of
National Institute on Aging (NIA)

Completed

Sodium-glucose Co Transporter 2 (sGLT2) Inhibitor and Endogenous Ketone Production

Physiological Effects of Drugs | Hypoglycemic Agents | Empaglifozin | Sodium-Glucose Transporter 2 Inhibitors

United States
Mario Negri Institute for Pharmacological Research
Boehringer Ingelheim

Withdrawn

SGLT2 Inhibitors in Glomerular Hyperfiltration (EMPATHY)

Obesity | Non-diabetic Chronic Kidney Disease
Boehringer Ingelheim
Eli Lilly and Company

Completed

EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction (EMPEROR-Reduced)

Heart Failure

United States, Spain, Canada, Korea, Republic of, China, Germany, Belgium, Australia, Italy, United Kingdom, Argentina, Hungary, Czechia, Poland, Netherlands, Japan, Mexico, India, Brazil, France
Boehringer Ingelheim

Completed

JARDIANCE Regulartory Post Marketing Surveillance in Korean Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

Korea, Republic of
University of Miami
AstraZeneca

Completed

Dapagliflozin Effects on Epicardial Fat

Type 2 Diabetes

United States
Novartis Pharmaceuticals

Completed

Study of Pharmacodynamics of LIK066 in Overweight and Obese Women With Polycystic Ovary Syndrome (PCOS)

Polycystic Ovary Syndrome

Germany, United States
Boehringer Ingelheim
Eli Lilly and Company

Completed

This Study Tests Empagliflozin in Patients With Chronic Heart Failure With Preserved Ejection Fraction (HFpEF). The Study Looks at How Far Patients Can Walk in 6 Minutes and at Their Heart Failure Symptoms.

Heart Failure

United States, Spain, Canada, Germany, Greece, Australia, Sweden, Italy, Norway, Poland, Portugal
The University of Texas Health Science Center at...
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Completed

SGLT2 Inhibition and Stimulation of Endogenous Glucose Production: Protocol 2

Type II Diabetes Mellitus

United States
Yonsei University

Completed

Impact of Dapagliflozin on DIAstolic Dysfunction in Type 2 Diabetic Patients

Type 2 Diabetes Mellitus

Korea, Republic of
Radboud University Medical Center

Completed

Effect of Dapagliflozin on IAH in T1DM

Hypoglycemia | Diabetes Mellitus, Type 1 | Hypoglycemia Unawareness

Netherlands
Yaounde Central Hospital

Completed

Short Term Effect of Empagliflozin in Hypertension (EMPHYT)

Hypertension

Cameroon
Theracos

Completed

Safety, Tolerability and Pharmacokinetics Study of EGT0001474 in Subjects With Type 2 Diabetes

Diabetes Mellitus Type 2

United States
Mitsubishi Tanabe Pharma Corporation

Completed

Long-Term Safety Study of Canagliflozin (TA-7284) in Combination With Insulin in Patients With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

Japan
AstraZeneca
Bristol-Myers Squibb

Completed

Phase III Insulin Add-On Asia Regional Program - ST

Diabetes

China, Korea, Republic of, Singapore
AstraZeneca
Bristol-Myers Squibb

Completed

Drug Interaction With Metformin

Healthy Male and Female Subjects

United States
Boehringer Ingelheim
Eli Lilly and Company

Completed

12 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Patients With Type 2 Diabetes Mellitus

Hypertension | Diabetes Mellitus, Type 2

United States, Canada, Czech Republic, Denmark, Estonia, Finland, France, Germany, Lebanon, Netherlands, Norway, Sweden
Boehringer Ingelheim

Completed

Equivalence of Resorption of Empagliflozin/Metformin Administered as Combination Tablet Compared With Empagliflozin/Metformin as Single Tablets Administered Together

Healthy

Germany
Boehringer Ingelheim

Completed

Relative Bioavailability BI 10773 and Metformin in Healthy Male Volunteers

Healthy
Children's Oncology Group
National Cancer Institute (NCI)

Active, not recruiting

Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome

Acute Myeloid Leukemia | Down Syndrome | Myelodysplastic Syndrome | Myeloproliferative Neoplasm | Myeloid Leukemia Associated With Down Syndrome

United States, Canada, Saudi Arabia, Puerto Rico, Australia, New Zealand
Martin Huelsmann

Recruiting

NT-proBNP Selected Prevention of Cardiac Events in Diabetic Patients

Heart Diseases | Diabetes Mellitus, Type 2

New Zealand, Austria, Netherlands, Spain, United Kingdom

Search clinical trials for: 2-deoxy-D-glucose (2DG)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Gambia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations